1. Wu C.Y., Young L., Young D., Martel J., Young J.D. Bions: a family of biomimetic mineralo-organic complexes derived from biological fluids. PLoS One. 2013; 8 (9): e75501. doi: 10.1371/journal.pone.0075501.
2. Kutikhin A.G., Velikanova E.A., Mukhamadiyarov R.A., Glushkova T.V., Borisov V.V., Matveeva V.G., Antonova L.V., Filip'ev D.E., Golovkin A.S., Shishkova D.K., Burago A.Y., Frolov A.V., Dolgov V.Y., Efimova O.S., Popova A.N., Malysheva V.Y., Vladimirov A.A., Sozinov S.A., Ismagilov Z.R., Russakov D.M., Lomzov A.A., Pyshnyi D.V., Gutakovsky A.K., Zhivodkov Y.A., Demidov E.A., Peltek S.E., Dolganyuk V.F., Babich O.O., Grigoriev E.V., Brusina E.B., Barbarash O.L., Yuzhalin A.E. Apoptosis-mediated endothelial toxicity but not direct calcification or functional changes in anticalcification proteins defines pathogenic effects of calcium phosphate bions. Sci Rep. 2016; 6: 27255. doi: 10.1038/srep27255.
3. Lind L., Skarfors E., Berglund L., Lithell H., Ljunghall S. Serum calcium: a new, independent, prospective risk factor for myocardial infarction in middle-aged men followed for 18 years. J Clin Epidemiol. 1997; 50 (8): 967-973. doi: 10.1016/S0895-4356(97)00104-2.
4. Foley R.N., Collins A.J., Ishani A., Kalra P.A. Calciumphosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2008; 156 (3): 556-563. doi: 10.1016/j.ahj.2008.05.016.
5. Palmer S.C., Hayen A., Macaskill P., Pellegrini F., Craig J.C., Elder G.J., Strippoli G.F. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011; 305 (11): 1119-1127. doi: 10.1001/jama.2011.308.
6. Reid I.R., Gamble G.D., Bolland M.J. Circulating calcium concentrations, vascular disease and mortality: a systematic review. J Intern Med. 2016; 279 (6): 524-540. doi: 10.1111/joim.12464.
7. Yurdagul A. Jr., Finney A.C., Woolard M.D., Orr A.W. The arterial microenvironment: the where and why of atherosclerosis. Biochem J. 2016; 473 (10): 1281-1295. doi: 10.1042/BJ20150844.
8. Gimbrone M.A. Jr., García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res. 2016; 118 (4): 620-636. doi: 10.1161/CIRCRESAHA.115.306301.
9. Jensen H.A., Mehta J.L. Endothelial cell dysfunction as a novel therapeutic target in atherosclerosis. Expert Rev Cardiovasc Ther. 2016; 14 (9): 1021-1033. doi: 10.1080/14779072.2016.1207527.
10. Cahill P.A., Redmond E.M. Vascular endothelium - Gatekeeper of vessel health. Atherosclerosis. 2016; 248: 97- 109. doi: 10.1016/j.atherosclerosis.2016.03.007.
11. Young J.D., Martel J., Young D., Young A., Hung C.M., Young L, Chao Y.J., Young J., Wu C.Y. Characterization of granulations of calcium and apatite in serum as pleomorphic mineralo-protein complexes and as precursors of putative nanobacteria. PLoS One. 2009; 4 (5): e5421. doi: 10.1371/journal.pone.0005421.
12. Peng H.H., Wu C.Y., Young D., Martel J., Young A., Ojcius D.M., Lee Y.H., Young J.D. Physicochemical and biological properties of biomimetic mineralo-protein nanoparticles formed spontaneously in biological fluids. Small. 2013; 9 (13): 2297-2307. doi: 10.1002/smll.201202270.
13. Young J.D., Martel J., Young L., Wu C.Y., Young A., Young D. Putative nanobacteria represent physiological remnants and culture by-products of normal calcium homeostasis. PLoS One. 2009; 4 (2): e4417. doi: 10.1371/journal.pone.0004417.
14. Martel J., Young D., Young A., Wu C.Y., Chen C.D., Yu J.S., Young J.D. Comprehensive proteomic analysis of mineralnanoparticles derived from human body fluids and analyzed by liquid chromatography-tandem mass spectrometry. Anal Biochem. 2011; 418 (1): 111-125. doi: 10.1016/j.ab.2011.06.018.
15. Smith E.R., Hanssen E., McMahon L.P., Holt S.G. Fetuin-A-containing calciprotein particles reduce mineral stress in the macrophage. PLoS One. 2013; 8 (4): e60904. doi: 10.1371/journal.pone.0060904.
16. Love S.A., Maurer-Jones M.A., Thompson J.W., Lin Y.S., Haynes C.L. Assessing nanoparticle toxicity. Annu Rev Anal Chem (Palo Alto Calif). 2012; 5: 181-205. doi: 10.1146/annurev-anchem-062011-143134.
17. Lai D.Y. Toward toxicity testing of nanomaterials in the 21st century: a paradigm for moving forward. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012; 4 (1): 1-15. doi: 10.1002/wnan.162.
18. Sukhanova A., Bozrova S., Sokolov P., Berestovoy M., Karaulov A., Nabiev I. Dependence of Nanoparticle Toxicity on Their Physical and Chemical Properties. Nanoscale Res Lett. 2018; 13 (1): 44. doi: 10.1186/s11671-018-2457-x.
19. Martel J., Wu C.Y., Hung C.Y., Wong T.Y., Cheng A.J., Cheng M.L., Shiao M.S., Young J.D. Fatty acids and small organic compounds bind to mineralo-organic nanoparticles derived from human body fluids as revealed by metabolomic analysis. Nanoscale. 2016; 8 (10): 5537-5545. doi: 10.1039/c5nr08116e.
20. Wu C.Y., Martel J., Young J.D. Comprehensive organic profiling of biological particles derived from blood. Sci Rep. 2018; 8 (1): 11310. doi: 10.1038/s41598-018-29573-6.
21. Барбараш Л.С., Рогулина Н.В., Рутковская Н.В., Овчаренко Е.А. Механизмы развития дисфункций биологических протезов клапанов сердца. Комплексные проблемы сердечно-сосудистых заболеваний. 2018; 7 (2): 10-24